TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01687218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Study: NCT01232738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline
Description: rasagiline 2 mg daily for 12 months
Study: NCT01687218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Study: NCT04953195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Tablets
Description: Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
Study: NCT00426881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Twice weekly resistance training for 52 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Once weekly resistance training for 52 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Twice weekly resistance training for 52 weeks.
Study: NCT02421354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00821340

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2-hRPE65
Description: Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
Study: NCT02421354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04422938

Intervention type: OTHER
Intervention: Manuel chest compressions handled by clinicians
Description: Compressions will be handled by human efforts

Intervention type: DEVICE
Intervention: LUCAS™ 2 Chest Compression System
Description: LUCAS-2 model piston-based mechanical chest compression device was used for mechanical chest compressions
Study: NCT01561417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: activated recombinant human factor VII
Description: One single dose administration, injected i.v. (into the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: One single dose administration, injected i.v. (into the vein)
Study: NCT00081887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Starting dose is 10 mg/m\^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
Study: NCT04313517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
Study: NCT00846586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study: NCT01754519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo wide local excision breast surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo SFRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04037176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
Study: NCT01125046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT04417595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil (Containing Omega-3 Acids)
Description: Fish Oil Supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Olive Oil Supplement
Study: NCT02620605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late Cabergoline 0.5mg
Description: Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
Study: NCT04845334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RR intervention
Description: The short psychological intervention consists of a narrative interview and a psychocorporeal intervention. Narrative interview: this is an interview aimed at exploring the experience and awareness of illness. The sharing of the dimension of pain and suffering, the verbalization of emotions, the narration of the history of illness, expectations and fears related to the intervention will be aimed at an emotional and cognitive restructuring of the experience of illness, improving the perception of internal resources and resilience.~Psycho-corporeal intervention:it is a training to the psychophysiological technique of the Relaxation Response (R.R.) of Hebert Benson (Mind-Body Medical Institute of Havard), aimed at stress management and consequently at reducing the perception of pain
Study: NCT02620605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Cabergoline 0.5mg
Description: Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
Study: NCT02982551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste Task
Description: Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
Study: NCT05078788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser uretherotomy
Description: Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser uretherotomy with triamcinolone
Description: After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
Study: NCT01012362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
Study: NCT04193540

Intervention type: OTHER
Intervention: ACE questionnaire
Description: Regardless of the result of the ACE questionnaire, physician, resident and nurse in charge of the patient will be asked their clinical opinion on decision-making capacity of the patient, based on a 4 steps Lickert scale and blindly of ACE result.
Study: NCT01533818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)\* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Syrup
Description: It will be given 2 times/day for 7 days
Study: NCT01164618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
Study: NCT04221672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin plus standard care
Description: All the participants received routine care after surgery. Intraoperative 1 mg, and 1 mg q12h from post-operative day 1 through day 4.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: All the participants received routine care after surgery only.
Study: NCT04265352

Intervention type: OTHER
Intervention: No intervension
Description: There is intervention at all.
Study: NCT00981877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GB (Florestor)
Description: S. Boulardii preparation of 1 gram twice daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRALB
Description: mixed probiotic preparation 1 gram twice daily for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GC (placebo)
Description: Placebo 1 gram twice daily for 5 days.
Study: NCT01720160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO® System
Description: Implant procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care medical managment therapy for heart failure
Description: Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care medical managment therapy for heart failure
Description: Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
Study: NCT03992391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide Prevention Intensive Outpatient Program
Description: participation in a suicide prevention intensive outpatient program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide Prevention Intensive Outpatient Program
Description: participation in a suicide prevention intensive outpatient program
Study: NCT03179735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride 0.7 mg/ml
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Study: NCT00989222

Intervention type: PROCEDURE
Group type: OTHER
Intervention: closed reduction and external fixation
Description: Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal fixation with a volar locked plate
Description: Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
Study: NCT02175225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine Mesylate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Deferoxamine Mesylate)
Study: NCT04028362

Intervention type: DRUG
Intervention: Neuromuscular Blocking Agents
Description: Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
Study: NCT02743364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Given PO
Study: NCT01753609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tulip capsule
Description: swallowing Tulip capsule for up to 29 days
Study: NCT04309032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter
Description: 0.9% NS 250cc was introduced before foley catheter removed for discharge
Study: NCT03017222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
Study: NCT04693429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate
Description: Bepotastine Besilate 1.5% QID (quater in die) for 7 days
Study: NCT03513016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent intra-articular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent intra-articular injection